Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

CREATES Act dropped but may still see progress

The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which aims to address healthcare costs by facilitating the entry of lower-cost generic and biosimilar versions, may face challenges for renewed congressional discussion this year due to competing priorities. However, two interviewed experts noted that with the pressure to decrease drug costs, CREATES could still be heard as part of the FY2019 budget debate, despite it being dropped from the 2018 budget bill.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top